Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73588285" target="_blank" >RIV/61989592:15110/18:73588285 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1080/03007995.2018.1490254" target="_blank" >http://dx.doi.org/10.1080/03007995.2018.1490254</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/03007995.2018.1490254" target="_blank" >10.1080/03007995.2018.1490254</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

Popis výsledku v původním jazyce

Objectives: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies, with non-conclusive results. Materials and methods: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stages IB (tumor of 4 cm in diameter), II, and IIIA, and reasons of AC omission were evaluated according to medical records. Mortality risk among patients treated with surgery (only) and different types of AC in routine practice was compared. Results: AC was applied to 79% of patients with stages IB (tumor of 4 cm in diameter), II, and IIIA, and was associated with an improved median of overall survival (HR¼0.69; 95% CI¼0.44–1.06). Significantly longer survival was achieved in the sub-group treated with platinum and oral vinorelbine (HR¼0.575, 95% CI¼0.339–0.974), and the longest survival was among patients treated with oral vinorelbine and cisplatin (HR¼0.371, 95% CI¼0.168–0.820). Conclusions: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.

Název v anglickém jazyce

Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

Popis výsledku anglicky

Objectives: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies, with non-conclusive results. Materials and methods: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stages IB (tumor of 4 cm in diameter), II, and IIIA, and reasons of AC omission were evaluated according to medical records. Mortality risk among patients treated with surgery (only) and different types of AC in routine practice was compared. Results: AC was applied to 79% of patients with stages IB (tumor of 4 cm in diameter), II, and IIIA, and was associated with an improved median of overall survival (HR¼0.69; 95% CI¼0.44–1.06). Significantly longer survival was achieved in the sub-group treated with platinum and oral vinorelbine (HR¼0.575, 95% CI¼0.339–0.974), and the longest survival was among patients treated with oral vinorelbine and cisplatin (HR¼0.371, 95% CI¼0.168–0.820). Conclusions: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

<a href="/cs/project/NV16-32318A" target="_blank" >NV16-32318A: Neinvazivní diagnostika karcinomů plic s použitím proteomických biomarkerů z dechového kondenzátu.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CURRENT MEDICAL RESEARCH AND OPINION

ISSN

0300-7995

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

1687-1694

Kód UT WoS článku

000441048500018

EID výsledku v databázi Scopus

2-s2.0-85049652060